ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2019 and some content may be unavailable. To unlock all content for 2019, please visit the archives.

Abstract: TH-PO965

Tubular Basement Membrane Deposits in Lupus Nephritis

Session Information

Category: Trainee Case Report

  • 1203 Glomerular Diseases: Clinical, Outcomes, and Trials

Authors

  • Malik, Anum, Cleveland Clinic Foundation, Cleveland, Ohio, United States
  • Abu Hweij, Roulan, Cleveland Clinic Foundation, Cleveland, Ohio, United States
  • Herlitz, Leal C., Cleveland Clinic Foundation, Cleveland, Ohio, United States
  • Nakhoul, Georges, Cleveland Clinic Foundation, Cleveland, Ohio, United States
Introduction

Glomerular lesions are the main renal finding in lupus nephritis (LN). Extraglomerular deposits can be observed in more than half of LN biopsies but are typically observed in conjunction with glomerular findings. We present a unique case of LN with tubulointerstitial inflammation secondary to prominent TBM immune deposits without glomerular activity.

Case Description

27 year old African American male with systemic lupus erythematosus (SLE) for 5 years, with biopsy proven LN class V, was admitted from nephrology clinic for work up of acute kidney injury. He was initially treated with hydroxychloroquine (HCQ) and prednisone at the time of his SLE diagnosis. On diagnosis of LN, 4 years later, mycophenolate mofetil (MMF) was added, which he was intolerant to and discontinued. He had 2 episodes of SLE flares for which rituximab was given. Azathioprine was added to his regimen of prednisone and HCQ after the second SLE flare. Prior to current presentation, the patient had started to taper his prednisone and was on 10mg daily. In this setting, his serum creatinine (SCr) rose to 4.32mg/dl from a baseline of 1.4-1.6mg/dl; C3 was low at 77; C4 was normal; dsDNA antibody was negative. He had an active urinary sediment. He was started on 125mg of methylprednisolone intravenously for 3 days. Renal biopsy was pursued to re-stage his LN and further determine the immunosuppression needed. Pathology showed active tubulointerstitial inflammation secondary to prominent TBM immune deposits without glomerular activity. He also had changes consistent with class V LN. He was discharged on oral prednisone 60mg daily, with a weekly 10mg taper, MMF 250mg daily, which he agreed to retry and HCQ 400 daily.

Discussion

Only 11 cases have shown predominant TBM LN in the literature. Studies have shown a correlation with TBM immune deposits and a twofold higher risk of end-stage renal disease or doubling of SCr after controlling for other factors. Thus, this finding is of prognostic significance. Treatment of predominant tubulointerstitial LN is not established. Most reported patients did not require cytotoxic immunosuppressive treatment and responded well to steroids alone.